Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in New York
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Education to Occupational Exposure Concerns
The legacy of general health and science information dissemination has long served as a foundation for public awareness, providing broad context for understanding medical conditions and therapeutic interventions. Within this framework, the transition from general health education to specific occupational exposure concerns requires a careful shift in focus. In the domain of mass production, where consistency and scale are paramount, the application of biological therapies introduces unique considerations for workforce safety. One such therapy, Tysabri, is used in the management of certain chronic conditions, and its association with Progressive Multifocal Leukoencephalopathy (PML) has been documented in clinical settings. This connection raises important questions for individuals who may have been exposed to the drug in a professional capacity, such as those involved in manufacturing, handling, or administration. The risk of PML, a serious brain infection, becomes a focal point when considering occupational exposure, as the potential for inadvertent contact or prolonged handling may differ from patient-centered contexts. This pivot from general health literacy to a more targeted concern about workplace exposure underscores the need for vigilance in environments where biological agents are produced or utilized. Understanding the legal implications, including the statute of limitations for claims in New York, is a critical next step for those seeking recourse after potential exposure.
Tysabri and PML: A Medical Overview
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed to alert healthcare professionals and patients to the serious nature of this adverse effect. The clinical presentation of PML can be subtle and variable, often beginning with neurological symptoms such as progressive weakness, cognitive decline, visual disturbances, or coordination problems. Diagnosis typically requires brain imaging, usually magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), underscoring the gravity of this complication.
Mechanism of PML Risk and FDA Warnings
The mechanistic pathway linking Tysabri to PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance in the brain. Under normal conditions, immune cells help control JC virus, which is latent in many individuals. When Tysabri blocks immune cell entry, the virus can reactivate and cause PML. The FDA label identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibodies indicate prior exposure to the virus, longer treatment duration (especially beyond two years) increases cumulative risk, and prior immunosuppressant use further compromises immune function. The adequacy of warnings regarding Tysabri and PML is a central concern for affected patients and their attorneys. The FDA label includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to ensure that patients are informed of the risks and monitored for symptoms. The label states: "Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings were sufficiently clear or timely, particularly for patients who developed PML after prolonged therapy.
Legal Considerations: Statute of Limitations in New York
For patients in New York who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a lawsuit. In New York, the statute of limitations for personal injury claims generally is three years from the date of injury. However, for medical malpractice or product liability claims, the timeline may vary. The "discovery rule" may apply, meaning the clock starts when the patient knew or should have known that the injury was caused by the drug. Given that PML can develop months to years after starting Tysabri, and symptoms may be initially attributed to multiple sclerosis, the date of discovery can be complex. The FDA label notes that PML risk increases with "longer treatment duration, especially beyond 2 years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), so patients who have been on therapy for extended periods should be particularly vigilant. Attorneys representing affected patients must carefully document the timeline between Tysabri exposure and the onset of PML symptoms, as well as the date of definitive diagnosis, to ensure claims are filed within the statutory period. The timeline between exposure and documented harm is critical in PML cases. The FDA label states that PML has occurred in patients who have received Tysabri, and risk factors include duration of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While the label does not specify an exact latency period, clinical data suggest that PML typically occurs after at least several months of treatment, with risk increasing significantly after two years. For patients who develop PML, the outcome is often devastating, with death or severe disability being common. The label warns that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), emphasizing the need for prompt action if symptoms arise.
Adverse Event Reporting and Monitoring
The FDA adverse event reporting system (FAERS) lists fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported adverse events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are not specific to PML, they highlight the range of neurological symptoms that could overlap with early PML signs, potentially delaying diagnosis. In summary, Tysabri-associated PML is a serious and often fatal complication with well-defined risk factors. The FDA has mandated warnings and a restricted distribution program, but affected patients may still face challenges in timely diagnosis and legal recourse. For New York patients, understanding the statute of limitations and the discovery rule is essential when consulting an attorney. The evidence underscores the importance of monitoring for PML symptoms and considering legal options promptly after diagnosis.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in New York?
In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, for product liability or medical malpractice claims, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused the PML. Given the latency of PML, it is crucial to consult an attorney promptly after diagnosis.
What are the risk factors for developing PML from Tysabri?
Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid via PCR. Symptoms may include progressive weakness, cognitive decline, visual disturbances, or coordination problems. Early diagnosis is critical due to the high risk of death or severe disability.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.